scholarly journals A Case Report on Alcohol Dependence Syndrome with Cannabis Addiction

2021 ◽  
pp. 439-444
Author(s):  
Deepti Ekhar ◽  
Samual Vanlalpeka ◽  
Shabnam Sayyad ◽  
Dharti Meshram ◽  
Trupti Uke ◽  
...  
Keyword(s):  
Case Report ◽  
Alcohol Dependence ◽  
Case Reports ◽  
Public Mental Health ◽  
Behavioural Therapy ◽  
Positive Outcomes ◽  
First Line ◽  
Psychopharmacological Treatment ◽  
Cognitive Behavioural ◽  
Alcohol Dependence Syndrome

Background: Alcohol dependence syndrome (ADS) and Cannabis use disorder (CUD) are every now and again co-happening or comorbid substance issues in the two young people and grown-ups. Indications of cross-over between ADS and CUD in people as they slowly move from pre-adulthood to adulthood. The researchers reasoned that the two substance-related issues are comorbid, albeit the closeness of their association ordinarily shifts over the long haul. Aim and Objective: The purpose of this case report is to determine the first-line approach for a person with alcohol dependence syndrome with cannabis addiction who has been referred to a public mental health facility for treatment. To identifying symptoms of ADS with cannabis addiction early, providing treatment and preventing possible complications. Methods: Knowledge used to write this case description was gathered from PubMed outlets, search hand, searching college and personal libraries looking for research techniques and case report texts, engaging in or writing many case reports with experience.  Results: The patient was taken psychopharmacological treatment Anti- Anxiety drugs Lorazepam along with Tab. Benalgis, Tab. Neurobion fort and psycho social therapy, coping strategies, family therapy, yoga, cognitive behavioural therapy, medication. After those symptoms was minimized. Conclusion: Patients achieve positive outcomes not only through the support of their treatment management, but also through adaptation and family support. Then, with appropriate psychophysiological treatment, the patient gave a positive response and gradually all the planned goals were achieved. Finally, the patient was discharged and he is currently being monitored.

scholarly journals A Clinical Case Report: Schizophrenia

2021 ◽  
pp. 428-433
Author(s):  
Deepti Ekhar ◽  
Jaya Gawai ◽  
Pooja Kasturkar
Keyword(s):  
Case Report ◽  
Antipsychotic Drugs ◽  
Positive Response ◽  
Case Reports ◽  
Public Mental Health ◽  
Behavioural Therapy ◽  
Positive Outcomes ◽  
First Line ◽  
Psychopharmacological Treatment ◽  
Cognitive Behavioural

Background: Schizophrenia (SCZ) is a serious mental disorder in which people take reality as abnormally. SCZ may cause in combination of hallucination, delusions, and extremely disorder thinking and behaviour that impairs daily functioning and cannot be disabling. There are different reasons of SCZ this may be as of Genes, Environment or Change in Brain Structures.In India around 3/1000 people were affected due to SCZ Aim: The purpose of this case report is to determine the first line approach for a person with SCZ who has been referred to a public mental health facility for treatment. Objective: To identifying symptoms of SCZ early, providing treatment and preventing possible complications. Methods: Knowledge used to write this case description was gathered from PubMed outlets, search hand, searching college and personal libraries looking for research techniques and case report texts, engaging in or writing many case reports with experience. Results: The patient was taken psychopharmacological treatment antipsychotic drugs olanzapine, Risperidone along with antidepressant Sertraline and psycho social therapy, coping strategies, family therapy, yoga, cognitive behavioural therapy, medication. After those symptoms was minimized. Conclusion: Patients achieve positive outcomes not only through the support of their treatment management, but also through adaptation and familysupport. subsequently, with appropriate psychophysiological treatment, the patient gave a positive response and gradually all the planned goalswere achieved. Finally, the patient was discharged and she is currently beingmonitored.

scholarly journals Efficacy and moderators of efficacy of trauma-focused cognitive behavioural therapies in children and adolescents: protocol for an individual participant data meta-analysis from randomised trials

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e047212
Author(s):  
Anke de Haan ◽  
Caitlin Hitchcock ◽  
Richard Meiser-Stedman ◽  
Markus A Landolt ◽  
Isla Kuhn ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Meta Analysis ◽  
Behavioural Therapy ◽  
Risk Of Bias ◽  
Randomised Trials ◽  
First Line ◽  
Cognitive Behavioural ◽  
Individual Participant ◽  
Behavioural Therapies ◽  
First Line Treatment

IntroductionTrauma-focused cognitive behavioural therapies are the first-line treatment for posttraumatic stress disorder (PTSD) in children and adolescents. Nevertheless, open questions remain with respect to efficacy: why does this first-line treatment not work for everyone? For whom does it work best? Individual clinical trials often do not provide sufficient statistical power to examine and substantiate moderating factors. To overcome the issue of limited power, an individual participant data meta-analysis of randomised trials evaluating forms of trauma-focused cognitive behavioural therapy in children and adolescents aged 6–18 years will be conducted.Methods and analysisWe will update the National Institute for Health and Care Excellence guideline literature search from 2018 with an electronic search in the databases PsycINFO, MEDLINE, Embase, Cochrane Central Register of Controlled Trials and CINAHL with the terms (trauma* OR stress*) AND (cognitive therap* OR psychotherap*) AND (trial* OR review*). Electronic searches will be supplemented by a comprehensive grey literature search in archives and trial registries. Only randomised trials that used any manualised psychological treatment—that is a trauma-focused cognitive behavioural therapy for children and adolescents—will be included. The primary outcome variable will be child-reported posttraumatic stress symptoms (PTSS) post-treatment. Proxy-reports (teacher, parent and caregiver) will be analysed separately. Secondary outcomes will include follow-up assessments of PTSS, PTSD diagnosis and symptoms of comorbid disorders such as depression, anxiety-related and externalising problems. Random-effects models applying restricted maximum likelihood estimation will be used for all analyses. We will use the Revised Cochrane Risk of Bias tool to measure risk of bias.Ethics and disseminationContributing study authors need to have permission to share anonymised data. Contributing studies will be required to remove patient identifiers before providing their data. Results will be published in a peer-reviewed journal and presented at international conferences.PROSPERO registration numberCRD42019151954.

California rocket fuel: And what about being a first line treatment?

2016 ◽  
Vol 33 (S1) ◽  
pp. S551-S551
Author(s):  
J. Silva ◽  
J. Mota ◽  
P. Azevedo
Keyword(s):  
Case Report ◽  
Depressive Symptoms ◽  
Case Reports ◽  
Drug Resistant ◽  
Line Treatment ◽  
First Line ◽  
Depressed Woman ◽  
Rocket Fuel ◽  
Resistant Depression ◽  
First Line Treatment

IntroductionThe association venlafaxine-mirtazapine is currently known as California Rocket Fuel (CRF). Studies show advantage in terms of efficacy and rapid control of depressive symptoms compared to other associations. Venlafaxine is a selective serotonin-noradrenalin reuptake inhibitor and mirtazapine is a noradrenergic-specific serotonergic antidepressant: the result is a potent noradrenergic and serotonergic effect. Studies say that CRF should be performed only for drug-resistant depression; however, there are case reports of its use as a first line treatment, in selected patients.ObjectivesTo summarize the latest literature about this field and to present a case report.AimTo explore and critically review the controversies of venlafaxine-mirtazapine association as a first line antidepressants strategy.MethodsA brief review of the latest literature was performed, using PubMed and the keywords “venlafaxine-mirtazapine association”. A case report about a depressed woman is presented.ResultsDespite most studies are referent to its utility in drug-resistant depression, there are recent pilot studies that recommend CRF as a first line option.M., a 64-year-old woman, had her first psychiatric consultation. She had been depressed for 2 years, she lost 10 kg, had total insomnia and suicidal thoughts. CRF was started up to 150/15 mg, daily. An improvement was noticed after two weeks of treatment and the stabilization of depressive symptoms were achieved by the fourth month.ConclusionsCRF seems to be effective and useful. Patients with insomnia and weight loss may benefit from CRF as a first line option. However, more studies are needed.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals A Clinicl Case Report on Black Dog (Depression)

2021 ◽  
pp. 181-185
Author(s):  
Dharti Meshram ◽  
Jaya Gawai ◽  
Pooja Kasturkar
Keyword(s):  
Case Report ◽  
Suicide Ideation ◽  
Social Withdrawal ◽  
Antidepressant Drug ◽  
Public Mental Health ◽  
Positive Outcome ◽  
Psychiatric Ward ◽  
Family Coping ◽  
Somatic Therapy ◽  
Psychopharmacological Treatment

Aim: - The intent of this case report is to define the top practice for a person detected with depressive disorder who has been denoted to a public mental health facility for treatment. To identify the black dog symptoms early to provide treatment and prevent potential complication. Presentation of case: A 45-year-old male patient got admitted in psychiatric ward AVBR Hospital Sawangi Meghe Wardha, Maharashtra, with the complaints of insomnia, low mood, social withdrawal, irritable, lack of interaction, lack of interest, sadness, hopelessness, helplessness, decrease appetite and suicide ideation such as hanging. patient was apparently asymptomatic 10 month ago when his younger brother passes away and his started show above clinical features of depression. patient received antidepressant drug citalopram, Imipramine and two-time Somatic therapy (Electroconvulsive Therapy). symptoms were minimized. Result: The patient was received psychopharmacological treatment antidepressant drug sertraline, citalopram, fluvoxamine along with somatic therapy (ECT) two times and psychosocial therapy, coping strategies, family therapy, yoga, recreation, meditation and symptoms was minimized. Discussion: Millions of people worldwide suffer from depression. it is most common disorder in outpatient clinic. which can result impairment and disability of individual ability to cope up with daily life. Conclusion: A positive outcome gets by the patient not only with the help of therapeutic management but also the family coping and support even. later on, due to proper psychopharmacological treatment, patient shown positive feedback and slowly all the aims are achieved which were planned in period. Finally, the patient got discharged from the hospital and now he is continuing his on follow up.

Management and treatment of bipolar disorder

2020 ◽  
pp. 757-766
Author(s):  
Eduard Vieta ◽  
Isabella Pacchiarotti ◽  
David J. Miklowitz
Keyword(s):  
Bipolar Disorder ◽  
Bipolar Depression ◽  
Preliminary Evidence ◽  
Behavioural Therapy ◽  
Dopamine Antagonists ◽  
Third Wave ◽  
First Line ◽  
Cognitive Behavioural ◽  
Social Rhythm ◽  
Long Acting

This chapter surveys the literature on the pharmacological and psychological management of bipolar disorder. Lithium, valproate, and several dopamine antagonists/partial agonists—in monotherapy or in combination—are the first-line treatments for acute mania. For bipolar depression, lithium, lamotrigine, and quetiapine monotherapy remain the first-line options. The topic of antidepressants in bipolar disorder is controversial. Lithium, lamotrigine, valproate, olanzapine, quetiapine, aripiprazole, risperidone, and long-acting antipsychotic formulations represent the principal strategies for maintenance treatment of bipolar disorder. The use of medication in bipolar disorder may benefit from a combined psychological approach in stabilizing symptoms and preventing relapses. Three strategies have shown consistent empirical evidence: group psychoeducation, family-focused therapy, and interpersonal and social rhythm therapy. The evidence supporting cognitive behavioural therapy (CBT) as an adjunctive psychosocial intervention is inconsistent, although ‘third-wave’ CBT approaches are promising. There is preliminary evidence for functional remediation in bipolar disorder patients with neurocognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document